A Novel Immune Gene-Related Prognostic Score Predicts Survival and Immunotherapy Response in Glioma
<i>Background and Objectives:</i> The clinical prognosis and survival prediction of glioma based on gene signatures derived from heterogeneous tumor cells are unsatisfactory. This study aimed to construct an immune gene-related prognostic score model to predict the prognosis of glioma an...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-12-01
|
| Series: | Medicina |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1648-9144/59/1/23 |
| _version_ | 1797438936671322112 |
|---|---|
| author | Xuehui Luo Qi Wang Hanmin Tang Yuetong Chen Xinyue Li Jie Chen Xinyue Zhang Yuesen Li Jiahao Sun Suxia Han |
| author_facet | Xuehui Luo Qi Wang Hanmin Tang Yuetong Chen Xinyue Li Jie Chen Xinyue Zhang Yuesen Li Jiahao Sun Suxia Han |
| author_sort | Xuehui Luo |
| collection | DOAJ |
| description | <i>Background and Objectives:</i> The clinical prognosis and survival prediction of glioma based on gene signatures derived from heterogeneous tumor cells are unsatisfactory. This study aimed to construct an immune gene-related prognostic score model to predict the prognosis of glioma and identify patients who may benefit from immunotherapy. <i>Methods:</i> 23 immune-related genes (IRGs) associated with glioma prognosis were identified through weighted gene co-expression network analysis (WGCNA) and Univariate Cox regression analysis based on large-scale RNA-seq data. Eight IRGs were retained as candidate predictors and formed an immune gene-related prognostic score (IGRPS) by multifactorial Cox regression analysis. The potential efficacy of immune checkpoint blockade (ICB) therapy of different subgroups was compared by The Tumor Immune Dysfunction and Exclusion (TIDE) algorithm. We further adopted a series of bioinformatic methods to characterize the differences in clinicopathological features and the immune microenvironment between the different risk groups. Finally, a nomogram integrating IGRPS and clinicopathological characteristics was built to accurately predict the prognosis of glioma. <i>Results:</i> Patients in the low-risk group had a better prognosis than those in the high-risk group. Patients in the high-risk group showed higher TIDE scores and poorer responses to ICB therapy, while patients in the low-risk group may benefit more from ICB therapy. The distribution of age and tumor grade between the two subgroups was significantly different. Patients with low IGRPS harbor a high proportion of natural killer cells and are sensitive to ICB treatment. While patients with high IGRPS display relatively poor prognosis, a higher expression level of DNA mismatch repair genes, high infiltrating of immunosuppressive cells, and poor ICB therapeutic outcomes. <i>Conclusions:</i> We demonstrated that the IGRPS model can independently predict the clinical prognosis as well as the ICB therapy responses of glioma patients, thus having important implications on the design of immune-based therapeutic strategies. |
| first_indexed | 2024-03-09T11:45:30Z |
| format | Article |
| id | doaj.art-692d68061f77497a836a54eaa690cdeb |
| institution | Directory Open Access Journal |
| issn | 1010-660X 1648-9144 |
| language | English |
| last_indexed | 2024-03-09T11:45:30Z |
| publishDate | 2022-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Medicina |
| spelling | doaj.art-692d68061f77497a836a54eaa690cdeb2023-11-30T23:23:17ZengMDPI AGMedicina1010-660X1648-91442022-12-015912310.3390/medicina59010023A Novel Immune Gene-Related Prognostic Score Predicts Survival and Immunotherapy Response in GliomaXuehui Luo0Qi Wang1Hanmin Tang2Yuetong Chen3Xinyue Li4Jie Chen5Xinyue Zhang6Yuesen Li7Jiahao Sun8Suxia Han9Department of Radiation Oncology, First Affiliated Hospital of Xi’an Jiaotong University, Xi’an 710049, ChinaDepartment of Radiation Oncology, First Affiliated Hospital of Xi’an Jiaotong University, Xi’an 710049, ChinaDepartment of Radiation Oncology, First Affiliated Hospital of Xi’an Jiaotong University, Xi’an 710049, ChinaDepartment of Radiation Oncology, First Affiliated Hospital of Xi’an Jiaotong University, Xi’an 710049, ChinaDepartment of Radiation Oncology, First Affiliated Hospital of Xi’an Jiaotong University, Xi’an 710049, ChinaDepartment of Radiation Oncology, First Affiliated Hospital of Xi’an Jiaotong University, Xi’an 710049, ChinaDepartment of Radiation Oncology, First Affiliated Hospital of Xi’an Jiaotong University, Xi’an 710049, ChinaDepartment of Radiation Oncology, First Affiliated Hospital of Xi’an Jiaotong University, Xi’an 710049, ChinaDepartment of Radiation Oncology, First Affiliated Hospital of Xi’an Jiaotong University, Xi’an 710049, ChinaDepartment of Radiation Oncology, First Affiliated Hospital of Xi’an Jiaotong University, Xi’an 710049, China<i>Background and Objectives:</i> The clinical prognosis and survival prediction of glioma based on gene signatures derived from heterogeneous tumor cells are unsatisfactory. This study aimed to construct an immune gene-related prognostic score model to predict the prognosis of glioma and identify patients who may benefit from immunotherapy. <i>Methods:</i> 23 immune-related genes (IRGs) associated with glioma prognosis were identified through weighted gene co-expression network analysis (WGCNA) and Univariate Cox regression analysis based on large-scale RNA-seq data. Eight IRGs were retained as candidate predictors and formed an immune gene-related prognostic score (IGRPS) by multifactorial Cox regression analysis. The potential efficacy of immune checkpoint blockade (ICB) therapy of different subgroups was compared by The Tumor Immune Dysfunction and Exclusion (TIDE) algorithm. We further adopted a series of bioinformatic methods to characterize the differences in clinicopathological features and the immune microenvironment between the different risk groups. Finally, a nomogram integrating IGRPS and clinicopathological characteristics was built to accurately predict the prognosis of glioma. <i>Results:</i> Patients in the low-risk group had a better prognosis than those in the high-risk group. Patients in the high-risk group showed higher TIDE scores and poorer responses to ICB therapy, while patients in the low-risk group may benefit more from ICB therapy. The distribution of age and tumor grade between the two subgroups was significantly different. Patients with low IGRPS harbor a high proportion of natural killer cells and are sensitive to ICB treatment. While patients with high IGRPS display relatively poor prognosis, a higher expression level of DNA mismatch repair genes, high infiltrating of immunosuppressive cells, and poor ICB therapeutic outcomes. <i>Conclusions:</i> We demonstrated that the IGRPS model can independently predict the clinical prognosis as well as the ICB therapy responses of glioma patients, thus having important implications on the design of immune-based therapeutic strategies.https://www.mdpi.com/1648-9144/59/1/23RNA sequencingimmune-related geneprognostic biomarkergliomaimmune checkpoint blockadetumor immune microenvironment |
| spellingShingle | Xuehui Luo Qi Wang Hanmin Tang Yuetong Chen Xinyue Li Jie Chen Xinyue Zhang Yuesen Li Jiahao Sun Suxia Han A Novel Immune Gene-Related Prognostic Score Predicts Survival and Immunotherapy Response in Glioma Medicina RNA sequencing immune-related gene prognostic biomarker glioma immune checkpoint blockade tumor immune microenvironment |
| title | A Novel Immune Gene-Related Prognostic Score Predicts Survival and Immunotherapy Response in Glioma |
| title_full | A Novel Immune Gene-Related Prognostic Score Predicts Survival and Immunotherapy Response in Glioma |
| title_fullStr | A Novel Immune Gene-Related Prognostic Score Predicts Survival and Immunotherapy Response in Glioma |
| title_full_unstemmed | A Novel Immune Gene-Related Prognostic Score Predicts Survival and Immunotherapy Response in Glioma |
| title_short | A Novel Immune Gene-Related Prognostic Score Predicts Survival and Immunotherapy Response in Glioma |
| title_sort | novel immune gene related prognostic score predicts survival and immunotherapy response in glioma |
| topic | RNA sequencing immune-related gene prognostic biomarker glioma immune checkpoint blockade tumor immune microenvironment |
| url | https://www.mdpi.com/1648-9144/59/1/23 |
| work_keys_str_mv | AT xuehuiluo anovelimmunegenerelatedprognosticscorepredictssurvivalandimmunotherapyresponseinglioma AT qiwang anovelimmunegenerelatedprognosticscorepredictssurvivalandimmunotherapyresponseinglioma AT hanmintang anovelimmunegenerelatedprognosticscorepredictssurvivalandimmunotherapyresponseinglioma AT yuetongchen anovelimmunegenerelatedprognosticscorepredictssurvivalandimmunotherapyresponseinglioma AT xinyueli anovelimmunegenerelatedprognosticscorepredictssurvivalandimmunotherapyresponseinglioma AT jiechen anovelimmunegenerelatedprognosticscorepredictssurvivalandimmunotherapyresponseinglioma AT xinyuezhang anovelimmunegenerelatedprognosticscorepredictssurvivalandimmunotherapyresponseinglioma AT yuesenli anovelimmunegenerelatedprognosticscorepredictssurvivalandimmunotherapyresponseinglioma AT jiahaosun anovelimmunegenerelatedprognosticscorepredictssurvivalandimmunotherapyresponseinglioma AT suxiahan anovelimmunegenerelatedprognosticscorepredictssurvivalandimmunotherapyresponseinglioma AT xuehuiluo novelimmunegenerelatedprognosticscorepredictssurvivalandimmunotherapyresponseinglioma AT qiwang novelimmunegenerelatedprognosticscorepredictssurvivalandimmunotherapyresponseinglioma AT hanmintang novelimmunegenerelatedprognosticscorepredictssurvivalandimmunotherapyresponseinglioma AT yuetongchen novelimmunegenerelatedprognosticscorepredictssurvivalandimmunotherapyresponseinglioma AT xinyueli novelimmunegenerelatedprognosticscorepredictssurvivalandimmunotherapyresponseinglioma AT jiechen novelimmunegenerelatedprognosticscorepredictssurvivalandimmunotherapyresponseinglioma AT xinyuezhang novelimmunegenerelatedprognosticscorepredictssurvivalandimmunotherapyresponseinglioma AT yuesenli novelimmunegenerelatedprognosticscorepredictssurvivalandimmunotherapyresponseinglioma AT jiahaosun novelimmunegenerelatedprognosticscorepredictssurvivalandimmunotherapyresponseinglioma AT suxiahan novelimmunegenerelatedprognosticscorepredictssurvivalandimmunotherapyresponseinglioma |